MAP2K7 and thyroid tumor: Dabrafenib inhibits mutated BRAF proteins and trametinib inhibits MEK. Neither dabrafenib nor trametinib is currently approved for papillary thyroid cancer, however responses have been observed to those drugs in thyroid tumors carrying the BRAFV600 mutation.